Cargando…

Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry

AIMS: The introduction of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) is likely to change the approach to the management of patients with chronic heart failure with reduced ejection fraction (HFrEF). The Assessment of Real Life Care–Describing European Heart Failure Managemen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeymer, Uwe, Clark, Andrew L., Barrios, Vivencio, Damy, Thibaud, Drożdż, Jaroslaw, Fonseca, Candida, Lund, Lars H., Comite, Gabriele Di, Hupfer, Stephan, Maggioni, Aldo P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Study Designs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160498/ https://www.ncbi.nlm.nih.gov/pubmed/32027782 http://dx.doi.org/10.1002/ehf2.12569

Ejemplares similares

Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
por: Maggioni, Aldo P., et al.
Publicado: (2022)

Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry
por: Henkens, Michiel T.H.M., et al.
Publicado: (2022)

German Cardiac Arrest Registry: rationale and design of G-CAR
por: Pöss, Janine, et al.
Publicado: (2022)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
por: Scheffer, Mariëlle, et al.
Publicado: (2020)

Personalized pacing for diastolic dysfunction and heart failure with preserved ejection fraction: Design and rationale for the myPACE randomized controlled trial
por: Infeld, Margaret, et al.
Publicado: (2021)

Rationale and design of a navigator‐driven remote optimization of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction
por: Blood, Alexander J., et al.
Publicado: (2019)

Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild‐type cardiac amyloidosis
por: Kharoubi, Mounira, et al.
Publicado: (2020)

Rationale and Study Design of Differences in Cardiopulmonary Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition in Patients with Suspected Heart Failure with Preserved Ejection Fraction
por: Kim, So Ree, et al.
Publicado: (2021)

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
por: McMurray, John J.V., et al.
Publicado: (2019)

Ariadne auf Naxos
por: Strauss, Richard, 1864-1949
Publicado: (1988)

ARIADNE at HERPA and at the LHC
por: Lönnblad, L
Publicado: (2005)

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve‐HR trial)
por: Palau, Patricia, et al.
Publicado: (2020)

International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT‐HF): rationale for and design of a global registry
por: Filippatos, Gerasimos, et al.
Publicado: (2015)

TranslatiOnal Registry for CardiomyopatHies (TORCH) – rationale and first results
por: Seyler, Claudia, et al.
Publicado: (2017)

Setting a benchmark for resource utilization and quality of care in patients undergoing transcatheter aortic valve implantation in Europe—Rationale and design of the international BENCHMARK registry
por: McCalmont, Gemma, et al.
Publicado: (2021)

Regional management of worsening heart failure: rationale and design of the CHAIN‐HF registry
por: Shakoor, Abdul, et al.
Publicado: (2023)

Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease
por: Sorbets, Emmanuel, et al.
Publicado: (2017)

Contemporary use and trends in percutaneous coronary intervention in Japan: an outline of the J-PCI registry
por: Sawano, Mitsuaki, et al.
Publicado: (2020)

Real‐world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMART‐ Registry
por: Gardner, Roy S., et al.
Publicado: (2021)

Design and rationale of the North Indian ST‐Segment Elevation Myocardial Infarction Registry: A prospective cohort study
por: Arora, Sameer, et al.
Publicado: (2019)

Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry
por: Pereira, Naveen L., et al.
Publicado: (2021)

Ischemic Cardiomyopathy versus Non-Ischemic Dilated Cardiomyopathy in Patients with Reduced Ejection Fraction— Clinical Characteristics and Prognosis Depending on Heart Failure Etiology (Data from European Society of Cardiology Heart Failure Registries)
por: Tymińska, Agata, et al.
Publicado: (2022)

Wake Forest University long‐term follow‐up of type 2 myocardial infarction: The Wake‐Up T2MI Registry
por: Jogu, Hanumantha R., et al.
Publicado: (2019)

Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry
por: Berman, Adam N., et al.
Publicado: (2020)

Redesigning a large school-based clinical trial in response to changes in community practice
por: Gerald, Lynn B, et al.
Publicado: (2011)

Randomized trials of alcohol-use interventions with college students and their parents: lessons from the Transitions Project
por: Fernandez, AC, et al.
Publicado: (2011)

Evaluating the safety of a rotavirus vaccine: the REST of the story
por: Heyse, Joseph F, et al.
Publicado: (2008)

Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer
por: Demark-Wahnefried, Wendy, et al.
Publicado: (2008)

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
por: Reddy, K Rajender, et al.
Publicado: (2012)

A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen
por: Fiore, Louis D, et al.
Publicado: (2011)

The development and description of the comparison group in the Look AHEAD trial
Publicado: (2011)

Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design
por: Levin, Bruce, et al.
Publicado: (2011)

Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study
por: Connor, Jason T, et al.
Publicado: (2013)

Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014–2015 outbreak
por: Edwards, Tansy, et al.
Publicado: (2016)

Design of the HPTN 065 (TLC-Plus) study: A study to evaluate the feasibility of an enhanced test, link-to-care, plus treat approach for HIV prevention in the United States
por: Gamble, Theresa, et al.
Publicado: (2017)

The optimal design of stepped wedge trials with equal allocation to sequences and a comparison to other trial designs
por: Thompson, Jennifer A, et al.
Publicado: (2017)

Data on the Amphidinium carterae Dn241EHU isolation and morphological and molecular characterization
por: Seoane, S., et al.
Publicado: (2018)

Chromatin structure profile data from DNS-seq: Differential nuclease sensitivity mapping of four reference tissues of B73 maize (Zea mays L)
por: Turpin, Zachary M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_922v4j65e1gn4d4avg89pomd5o